Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2

Status

Active not recruiting 3Terminated 1Recruiting 1

Sponsor Class

OTHER 5NIH 5NETWORK 3

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 5

Conditions

Breast Neoplasms 2Anatomic Stage I Breast Cancer AJCC v8 2Inflammatory Breast Neoplasms 1Anatomic Stage II Breast Cancer AJCC v8 1

Interventions

pembrolizumab 603Cyclophosphamide 545Magnetic Resonance Spectroscopy 527Radiotherapy 513Specimen Handling 505Nivolumab 411Cisplatin 381Carboplatin 369Biopsy 305Blood Specimen Collection 304Radiosurgery 290Paclitaxel 281Gemcitabine 271Surveys and Questionnaires 269Standard of Care 267fludarabine 263Drug Therapy 263Dexamethasone 263Bevacizumab 252venetoclax 251Oxaliplatin 209Capecitabine 199Rituximab 198Radiation 191Ipilimumab 188Fluorouracil 188durvalumab 185Doxorubicin 178Etoposide 177atezolizumab 172

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
OTHER × 2C4 antibody × 1 year × Clear all
NCT04329065 2026-05-19

Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer

University of Washington

Phase 2 Recruiting
25 enrolled
Breast

Anatomic Stage I Breast Cancer AJCC v8

NCT05319873 2026-05-11

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

Jonsson Comprehensive Cancer Center

Phase 1/2 Active not recruiting
18 enrolled
Breast

Anatomic Stage II Breast Cancer AJCC v8

NCT03101748 2026-02-12

Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer

M.D. Anderson Cancer Center

Phase 1/2 Terminated
34 enrolled 15 charts
Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT07407920 2026-02-12

Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
120 enrolled
Breast

Anatomic Stage I Breast Cancer AJCC v8

NCT02827877 2025-11-14

Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer

City of Hope Medical Center

Phase 2 Active not recruiting
18 enrolled 8 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡